Accession Number: | 0001363213-15-000026 |
Date: | 2015-07-06 |
Issuer: | SCICLONE PHARMACEUTICALS INC (SCLN) |
Original Submission Date: |
BLOBEL FRIEDHELM
950 TOWER LANE, SUITE 900
FOSTER CITY, CA 94404
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2015-07-06 | M | 20,000 | a | $2.49 | 222,273 | direct | ||
COMMON STOCK | 2015-07-06 | S | 20,000 | d | $10.80 | 202,273 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NON-QUALIFIED STOCK OPTION (RIGHT TO BUY) | 2.49 | 2015-07-06 | deemed execution date | M | 20,000 (d) | 2016-06-02 | common stock 20,000 | $2.49 | 629,360 | direct |
ID | footnote |
---|---|
f1 | the reported sale was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on december 11, 2014. |
f2 | granted under the issuer's 2005 equity incentive plan. |
f3 | provided the reporting person remains employed by or acting as a consultant to the company, the option will become exercisable in four equal annual installments on 6/02/07, 6/02/08, 6/02/09 and 6/02/10. |